Elevation Oncology Inc
ELEV
Company Profile
Business description
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
Contact
101 Federal Street
Suite 1900
New YorkNY02110
USAT: +1 716 371-1125
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
34
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,578.50 | 53.70 | 0.63% |
| CAC 40 | 7,883.63 | 3.06 | -0.04% |
| DAX 40 | 23,934.98 | 167.55 | 0.70% |
| Dow JONES (US) | 42,792.07 | 137.33 | 0.32% |
| FTSE 100 | 8,699.31 | 14.75 | 0.17% |
| HKSE | 23,607.93 | 275.21 | 1.18% |
| NASDAQ | 19,215.46 | 4.36 | 0.02% |
| Nikkei 225 | 37,549.71 | 51.08 | 0.14% |
| NZX 50 Index | 12,644.23 | 15.16 | 0.12% |
| S&P 500 | 5,963.60 | 5.22 | 0.09% |
| S&P/ASX 200 | 8,349.00 | 53.90 | 0.65% |
| SSE Composite Index | 3,380.20 | 12.62 | 0.37% |